Novartis’ Hanekamp to lead commercial at BioNTech
Plus: New leaders for Bayer’s commercial team and updates from Intra-Cellular, Affyimmune, BenevolentAI, Bicycle and VolitionRx
BioNTech SE (NASDAQ:BNTX) named Annemarie Hanekamp as chief commercial officer, two weeks after the company announced the planned retirement of Sean Marett as chief business and commercial officer and its plans to separate the CBO and CCO functions. Hanekamp, whose appointment is effective July 1, is SVP, global head, radioligand therapy at Novartis AG (SIX:NOVN; NYSE:NVS), which she joined in 2021 after an 11-year career at Bristol Myers Squibb Co. (NYSE:BMY). She will be responsible for building a global commercial team ahead of BioNTech’s first oncology product launch, which is expected in 2026.
As part of a move to streamline its leadership, Bayer AG (Xetra:BAYN) named Sebastian Guth to the new role of COO, with responsibility for commercial operations in all markets, and Christine Roth as head of the company’s new global commercialization organization. Guth is president of Bayer U.S. and president of pharmaceuticals North America, while Roth is EVP, head of the oncology strategic business unit. Both will continue to report to Stefan Oelrich, president of Bayer’s pharmaceuticals division. ...